Tango Therapeutics, Inc.

Tango Therapeutics, Inc. is a precision oncology company focused on discovering and developing drugs for defined patient populations with unmet medical needs. The company's pipeline includes several investigational therapies targeting specific genetic alterations in cancer. For example, TNG462 is a methylthioadenosine-cooperative PRMT5 inhibitor currently in Phase 1/2 clinical trials for pancreatic and lung cancer. TNG456 is a brain-penetrant PRMT5 inhibitor being developed for glioblastoma. Additionally, TNG260 targets the co-repressor of repressor element-1 silencing transcription to reverse immune evasion caused by STK11 loss-of-function mutations in lung cancer. The company's approach aims to match treatments to patients whose tumors harbor specific genetic vulnerabilities.

Tango Therapeutics, Inc. is listed on the NasdaqGM exchange under the ticker symbol TNGX. The company's stock trades in US dollars (USD). As a US-based company listed on a major American exchange, its shares are accessible to investors through standard brokerage accounts. The NasdaqGM is a global market tier of the Nasdaq Stock Market, which lists many biotechnology and healthcare companies. Investors should be aware that trading in USD means currency exchange considerations apply for non-US investors.

Tango Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on using biological processes and genetic insights to develop new drugs, particularly in oncology. The company's precision oncology approach involves identifying specific genetic mutations in cancer cells and designing therapies that target those vulnerabilities. This places it at the intersection of drug discovery, molecular biology, and cancer treatment. The biotechnology industry is known for high research and development costs, long development timelines, and significant regulatory oversight, but also for the potential to address serious unmet medical needs.

Tango Therapeutics is headquartered in Boston, Massachusetts, United States. The company primarily serves the US market, as indicated by its listing on a US exchange and its focus on developing drugs for patient populations defined by genetic alterations. While the company's clinical trials may involve sites in multiple countries, its operations and strategic focus are centered in the United States. Boston is a major hub for biotechnology and pharmaceutical research, providing access to talent, academic collaborations, and a supportive ecosystem for drug development. The company's headquarters location supports its mission to advance precision oncology treatments.

Tango Therapeutics has several key drug candidates in development. TNG462 is a methylthioadenosine-cooperative PRMT5 inhibitor in Phase 1/2 clinical trials for treating pancreatic and lung cancer. TNG456 is a brain-penetrant PRMT5 inhibitor being developed for glioblastoma, a type of brain cancer. TNG260 is a co-repressor of repressor element-1 silencing transcription inhibitor designed to reverse immune evasion caused by STK11 loss-of-function mutations, primarily targeting lung cancer. These candidates represent the company's focus on addressing specific genetic vulnerabilities in cancer. All are in relatively early stages of clinical development, and their safety and efficacy have not yet been established for regulatory approval.